Aim: The renin–angiotensin–aldosterone system has been implicated in the pathogenesis of insulin resistance and nonalcoholic fatty liver disease (NAFLD). The beneficial effect of spironolactone in a mouse model with diabetes and NAFLD has recently been reported. The main aim was assessment of the effect of spironolactone on serum metabolic parameters and insulin resistance in patients with NAFLD.
Methods: This study includes preliminary results of a single-centre randomised controlled trial of treatment with vitamin E (group 1, 10 patients) versus spironolactone plus vitamin E (group 2, 10 patients) in biopsy-proven NAFLD. Serum transaminases, lipids, potassium, sodium, glucose and insulin were measured, and homeostatic model assessment-insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) were calculated before and 8weeks after baseline assessment.
Results: Insulin was decreased within group 2 (15.3 ± 2.7 at baseline vs. 10.3 ± 5.0 at week 8, p = 0.013). Although no difference in glucose was observed, HOMA-IR significantly decreased (4.4 ± 0.9 vs. 2.8 ± 0.5, respectively, p = 0.047). QUICKI was increased, but not statistically significantly.
Conclusions: Spironolactone and vitamin E combined therapy seems to exhibit a favourable effect on serum insulin and HOMA-IR in patients with NAFLD. If validated in a large-scale clinical trial, it may prove an inexpensive therapeutic approach for the management of NAFLD patients.
BellentaniSMarinoM. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol2009; 8(Suppl 1): 4–8.
2.
AhmedMHAbuEOByrneCD. Non-Alcoholic Fatty Liver Disease (NAFLD): New challenge for general practitioners and important burden for health authorities?Prim Care Diabetes2010; 4: 129–137.
3.
PolyzosSAKountourasJZavosC. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med2009; 72: 299–314.
4.
LewisJRMohantySR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci2010; 55: 560–578.
5.
PolyzosSAKountourasJZavosCTsiaousiE. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab2010; 12: 365–383.
6.
MussoGGambinoRCassaderMPaganoG. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology2010; 52: 79–104.
7.
SanyalAJChalasaniNKowdleyKV. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med2010; 362: 1675–1685.
8.
AthyrosVGMikhailidisDPDidangelosTP. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin2006; 22: 873–883.
9.
FilippatosTDElisafMS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol2010; 2: 139–142.
10.
HiroseAOnoMSaibaraT. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology2007; 45: 1375–1381.
11.
GiacchettiGSechiLARilliSCareyRM. The renin–angiotensin–aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab2005; 16: 120–126.
12.
BansalSLindenfeldJSchrierRW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?Circ Heart Fail2009; 2: 370–376.
13.
WadaTKenmochiH MiyashitaY. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology2010; 151: 2040–2049.
14.
KleinerDEBruntEMVan NattaM. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology2005; 41: 1313–1321.
15.
ChalasaniNPSanyalAJKowdleyKV. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials2009; 30: 88–96.
16.
MatthewsDRHoskerJPRudenskiASNaylorBATreacherDFTurnerRC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia1985; 28: 412–419.
17.
KatzANambiSSMatherK. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab2000; 85: 2402–2410.
18.
StruthersADMacDonaldTM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res2004; 61: 663–670.
19.
OyamadaNSoneMMiyashitaK. The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology2008; 149: 3764–3777.
20.
DorranceAM. Stroke therapy: is spironolactone the Holy Grail?Endocrinology2008; 149: 3761–3763.
WadaTOhshimaSFujisawaEKoyaDTsunekiHSasaokaT. Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes. Endocrinology2009; 150: 1662–1669.
23.
YamashitaRKikuchiTMoriY. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J2004; 51: 243–251.
24.
GuoCRicchiutiVLianBQ. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation2008; 117: 2253–2261.
25.
HirataAMaedaNHiugeA. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res2009; 84: 164–172.
26.
NoguchiRYoshijiHIkenakaY. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int J Mol Med2010; 26: 407–413.
27.
CatenaCLapennaRBaroselliS. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab2006; 91: 3457–3463.
28.
FalloFDallaPATecchioM. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study. Am J Hypertens2010; 23: 2–5.
29.
KebapcilarLTanerCEKebapcilarAGAlacaciogluASariI. Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. Arch Gynecol Obstet2009; (E-pub ahead of print).
30.
ZulianESartoratoPBenediniS. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest2005; 28: 49–53.
31.
NakhjavaniMHamidiSEsteghamatiAAbbasiMNosratian-JahromiSPasalarP. Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism. Br J Clin Pharmacol2009; 68: 634–637.
32.
YutakaMMifuneMKubotaEItohHSaitoI. Comparison of effects of low dose of spironolactone and a thiazide diuretic in patients with hypertension treated with an angiotensin-converting enzyme inhibitor or an angiotensin type 1 receptor blocker. Clin Exp Hypertens2009; 31: 648–656.
33.
UstundagATugrulAUstundagSSutNDemirkanB. The effects of spironolactone on nephron function in patients with diabetic nephropathy. Ren Fail2008; 30: 982–991.
34.
DavidsonMBWongAHamrahianAHStevensMSirajES. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin- converting enzyme inhibitors. Endocr Pract2008; 14: 985–992.
35.
MatsumotoSTakebayashiKAsoY. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism2006; 55: 1645–1652.
36.
KourounakisPNRekkaE. Effect of spironolactone on dimethyl mercury toxicity. A possible molecular mechanism. Arzneimittelforschung1994; 44: 1150–1153.
37.
MihasAAFosterMMBarnesSMihasTAHirschowitzBISpenneyJG. Modification of D-galactosamine-induced liver injury in the rat by spironolactone. Pharmacology1979; 18: 235–240.
38.
SkrhaJHaasTSindelkaG. Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab2004; 89: 135–141.
